Trial Profile
Analysis of the metabolic syndrome improvement with the orexin receptor antagonist
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2020
Price :
$35
*
At a glance
- Drugs Suvorexant (Primary)
- Indications Insomnia; Metabolic syndrome
- Focus Therapeutic Use
- 25 Nov 2020 Status changed from recruiting to discontinued.
- 05 Jun 2017 New trial record